This article is more than 5 years old. Information may no longer be current.

NDA for Inveltys to treat postoperative inflammation, pain accepted

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has accepted a new drug application for Inveltys, a product candidate for the treatment of inflammation and pain in ocular surgery patients, according to a press release from Kala Pharmaceuticals.

If approved, Inveltys (KPI-121 1%) would be the first twice-daily ocular corticosteroid indicated for the treatment of postoperative ocular inflammation and pain, as all other drugs currently on the market are indicated for four times a day, the release said.

It uses Kala’s mucus-penetrating particle technology to enhance drug penetration and distribution in ocular tissues.

In two phase 3 clinical trials, Inveltys showed statistical significance for its primary efficacy endpoints of complete resolution of inflammation and pain at day 8 through day 15 compared with placebo, according to the release.

Inveltys has a Prescription Drug User Fee Act date of Aug. 24.